» Articles » PMID: 25352753

MicroRNA-1 in Cardiac Diseases and Cancers

Overview
Specialty Pharmacology
Date 2014 Oct 30
PMID 25352753
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRs) are endogenous ≈22-nt non-coding RNAs that participate in the regulation of gene expression at post-transcriptional level. MiR-1 is one of the muscle-specific miRs, aberrant expression of miR-1 plays important roles in many physiological and pathological processes. In this review, we focus on the recent studies about miR-1 in cardiac diseases and cancers. The findings indicate that miR-1 may be a novel, important biomarker, and a potential therapeutic target in cardiac diseases and cancers.

Citing Articles

MicroRNAs in atrial fibrillation - have we discovered the Holy Grail or opened a Pandora's box?.

Balan A, Scridon A Front Pharmacol. 2025; 16:1535621.

PMID: 40012622 PMC: 11861496. DOI: 10.3389/fphar.2025.1535621.


microRNA-1 Regulates Metabolic Flexibility in Skeletal Muscle via Pyruvate Metabolism.

Ismaeel A, Peck B, Montgomery M, Burke B, Goh J, Kang G bioRxiv. 2024; .

PMID: 39149347 PMC: 11326265. DOI: 10.1101/2024.08.09.607377.


Deciphering the Role of microRNAs: Unveiling Clinical Biomarkers and Therapeutic Avenues in Atrial Fibrillation and Associated Stroke-A Systematic Review.

Boxhammer E, Dienhart C, Rezar R, Hoppe U, Lichtenauer M Int J Mol Sci. 2024; 25(10.

PMID: 38791605 PMC: 11122365. DOI: 10.3390/ijms25105568.


Targeting MicroRNAs with Small Molecules.

Tadesse K, Benhamou R Noncoding RNA. 2024; 10(2).

PMID: 38525736 PMC: 10961812. DOI: 10.3390/ncrna10020017.


Circulating microRNAs and Cytokines as Prognostic Biomarkers for Doxorubicin-Induced Cardiac Injury and for Evaluating the Effectiveness of an Exercise Intervention.

Jeyabal P, Bhagat A, Wang F, Roth M, Livingston J, Gilchrist S Clin Cancer Res. 2023; 29(21):4430-4440.

PMID: 37651264 PMC: 11370763. DOI: 10.1158/1078-0432.CCR-23-1055.


References
1.
Bostjancic E, Zidar N, Stajer D, Glavac D . MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology. 2009; 115(3):163-9. DOI: 10.1159/000268088. View

2.
Mazzone M, Comoglio P . The Met pathway: master switch and drug target in cancer progression. FASEB J. 2006; 20(10):1611-21. DOI: 10.1096/fj.06-5947rev. View

3.
Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nohata N . Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer. 2011; 106(2):405-13. PMC: 3261671. DOI: 10.1038/bjc.2011.462. View

4.
Gidlof O, Andersson P, van der Pals J, Gotberg M, Erlinge D . Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology. 2011; 118(4):217-26. DOI: 10.1159/000328869. View

5.
Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y . Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010; 28(10):1721-6. DOI: 10.1200/JCO.2009.24.9342. View